No Prescription |
 |
 | ||
|
TELMA 40 Micardis |
|
| ||
No Prescription » Prescription Drugs 15 » TELMA 40 Micardis Telmisartan is used alone or in combination with other medications to treat high blood pressure. Telmisartan is in a class of medications called angiotensin II receptor antagonists. It works by blocking the action of certain chemicals that tighten the blood vessels so blood flows more smoothly.Telmisartan is also used sometimes to treat congestive heart failure. Buy TELMA 40 Micardis and other Prescription Drugs 15 products online at Medstore. 598
About TELMA 40 Micardis: Product Type: Prescription Drugs 15 TELMA 40 ( Micardis Generic Telmisartan ) TELMA 40 (Micardis Generic Telmisartan) Micardis Generic Telmisartan 40mg Tabs 30 ( 3 x 10) Micardis Generic Telmisartan TELMA 40
View more Prescription Drugs 15 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
